Back to results
US 2023/0066286 A1Published application
Deuterated tryptamine derivatives and methods of use
AssigneeCybin IRL Limited
InventorsAlex NIVOROZHKIN, Michael PALFREYMAN
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.
Claims14
1-4. (canceled)
A compound, wherein the compound is:
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
6-26. (canceled)
A pharmaceutical composition comprising a compound and a pharmaceutically acceptable vehicle;
- wherein the compound is
- or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
37-38. (canceled)
Dependencies are inferred from the claim text.